Yuviwel is a drug owned by Ascendis Pharma Growth Disorders As. It is protected by 12 US drug patents filed in 2026 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Nov 12, 2042. Details of Yuviwel's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US10835578 | Cnp Prodrugs With Large Carrier Moieties |
Jan, 2037
(10 years from now) | Active |
| US11413351 | Cnp Prodrugs With Carrier Attachment At The Ring Moiety |
Jan, 2037
(10 years from now) | Active |
| US11154593 | Cnp Prodrugs With Large Carrier Moieties |
Jan, 2037
(10 years from now) | Active |
| US11311604 | Controlled-Release Cnp Agonists With Low Npr-C Binding |
Jan, 2037
(10 years from now) | Active |
| US11389510 | Controlled-Release Cnp Agonists With Low Initial Npr-B Activity |
Jan, 2037
(10 years from now) | Active |
| US11224661 | Controlled-Release Cnp Agonists With Increased Nep Stability |
Jan, 2037
(10 years from now) | Active |
| US8906847 | Prodrug comprising a drug linker conjugate |
Apr, 2031
(5 years from now) | Active |
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US12377133 | Dry Pharmaceutical Formulations Of Cnp Conjugates |
Nov, 2042
(16 years from now) | Active |
| US12239689 | Controlled-Release Cnp Agonists With Low Initial Npr-B Activity |
Jan, 2037
(10 years from now) | Active |
| US12083182 | Controlled-Release Cnp Agonists With Increased Nep Stability |
Jan, 2037
(10 years from now) | Active |
| US11389511 | Controlled-Release Cnp Agonists With Reduced Side-Effects |
Jan, 2037
(10 years from now) | Active |
| US12156917 | Cnp Prodrugs With Carrier Attachment At The Ring Moiety |
Jan, 2037
(10 years from now) | Active |
FDA has granted several exclusivities to Yuviwel. Till the time
these exclusivities
are active, no other company can market a generic or bioequivalent version of Yuviwel, regardless of the status of it's patents. These exclusivities hence play a crucial role in
delaying the generic
launch. Given below are details of the exclusivities granted to
Yuviwel.
Exclusivity Information
Yuviwel holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2033. Details of Yuviwel's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-516) | Feb 27, 2033 |
US patents provide insights into the exclusivity only within the United States, but
Yuviwel is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Yuviwel's family patents as well as insights into
ongoing legal events
on those patents.
Yuviwel's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Yuviwel's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Nov 12, 2042 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Yuviwel Generics:
There are no approved generic versions for Yuviwel as of now.
About Yuviwel
Yuviwel is a drug owned by Ascendis Pharma Growth Disorders As. Yuviwel uses Navepegritide as an active ingredient. Yuviwel was launched by Ascendis in 2026.
Approval Date:
Yuviwel was approved by FDA for market use on 27 February, 2026.
Active Ingredient:
Yuviwel uses Navepegritide as the active ingredient. Check out other Drugs and Companies using Navepegritide ingredient
Dosage:
Yuviwel is available in powder form for subcutaneous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 1.3MG/VIAL | POWDER | Prescription | SUBCUTANEOUS |
| 2.8MG/VIAL | POWDER | Prescription | SUBCUTANEOUS |
| 5.5MG/VIAL | POWDER | Prescription | SUBCUTANEOUS |